Leerink Partnrs Has Negative Outlook of Lantheus Q4 Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Research analysts at Leerink Partnrs cut their Q4 2025 EPS estimates for shares of Lantheus in a research report issued to clients and investors on Tuesday, July 29th. Leerink Partnrs analyst R. Ruiz now forecasts that the medical equipment provider will post earnings per share of $1.50 for the quarter, down from their prior forecast of $1.51. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ FY2026 earnings at $7.08 EPS.

A number of other analysts have also recently commented on LNTH. William Blair reiterated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Truist Financial reduced their price target on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. B. Riley reduced their price target on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating for the company in a research report on Monday, June 23rd. Finally, Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus currently has an average rating of “Moderate Buy” and a consensus target price of $131.20.

Lantheus Stock Down 0.5%

LNTH stock opened at $71.84 on Wednesday. The firm has a 50 day moving average of $77.85 and a 200 day moving average of $88.41. The stock has a market capitalization of $4.97 billion, a PE ratio of 20.41 and a beta of 0.12. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus has a 52 week low of $69.12 and a 52 week high of $118.21.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the business earned $1.69 earnings per share.

Hedge Funds Weigh In On Lantheus

Several institutional investors have recently made changes to their positions in LNTH. Janus Henderson Group PLC increased its holdings in shares of Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after purchasing an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC increased its holdings in Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after acquiring an additional 2,361,000 shares in the last quarter. TD Asset Management Inc increased its holdings in Lantheus by 1,028.0% in the 1st quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock worth $66,623,000 after acquiring an additional 622,100 shares in the last quarter. Nuveen LLC purchased a new stake in Lantheus in the 1st quarter worth $55,941,000. Finally, T. Rowe Price Investment Management Inc. boosted its stake in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the transaction, the director directly owned 318,650 shares of the company’s stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.